{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:36:39Z","timestamp":1791333399485,"version":"4.3.1"},"reference-count":47,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2017.0354","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:29:13Z","timestamp":1525253353000},"source":"Crossref","is-referenced-by-count":108,"title":["The Diagnosis and Treatment of Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.3238","author":[{"given":"Ana-Luisa","family":"Stefanski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Tomiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R\u00fcdiger","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"10.3238\/arztebl.2017.0354_ref1","doi-asserted-by":"crossref","unstructured":"Tomiak C, Dorner T: Sjogren\u2018s syndrome. Current aspects from a rheumatological point of view. Z Rheumatol 2006; 65: 505\u201317","DOI":"10.1007\/s00393-006-0101-0"},{"key":"10.3238\/arztebl.2017.0354_ref2","doi-asserted-by":"crossref","unstructured":"Qin B, Wang J, Yang Z, et al.: Epidemiology of primary Sj\u00f6gren\u2018s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74: 1983\u20139","DOI":"10.1136\/annrheumdis-2014-205375"},{"key":"10.3238\/arztebl.2017.0354_ref3","doi-asserted-by":"crossref","unstructured":"Westhoff G, Zink A: Epidemiology of primary Sjogren\u2018s syndrome. Z Rheumatol 2010; 69: 41\u20139","DOI":"10.1007\/s00393-009-0518-3"},{"key":"10.3238\/arztebl.2017.0354_ref4","doi-asserted-by":"crossref","unstructured":"Brito-Zeron P, Theander E, Baldini C, et al.: Early diagnosis of primary Sj\u00f6gren\u2018s syndrome: EULAR-SS task force clinical recommendations. Expert Rev Clin Immunol 2016; 12: 137\u201356","DOI":"10.1586\/1744666X.2016.1109449"},{"key":"10.3238\/arztebl.2017.0354_ref5","doi-asserted-by":"crossref","unstructured":"Fox PC, Bowman SJ, Segal B, et al.: Oral involvement in primary Sj\u00f6gren syndrome. J Am Dent Assoc 2008; 139: 1592\u2013601","DOI":"10.14219\/jada.archive.2008.0101"},{"key":"10.3238\/arztebl.2017.0354_ref6","doi-asserted-by":"crossref","unstructured":"Bron AJ, Tomlinson A, Foulks GN, et al.: Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf 2014; 12: 1\u201331","DOI":"10.1016\/j.jtos.2014.02.002"},{"key":"10.3238\/arztebl.2017.0354_ref7","doi-asserted-by":"crossref","unstructured":"Villa A, Abati S: Risk factors and symptoms associated with xerostomia: a cross-sectional study. Aust Dent J 2011; 56: 290\u20135","DOI":"10.1111\/j.1834-7819.2011.01347.x"},{"key":"10.3238\/arztebl.2017.0354_ref8","doi-asserted-by":"crossref","unstructured":"Cornec D, Saraux A, Jousse-Joulin S, et al.: The differential diagnosis of dry eyes, dry mouth, and parotidomegaly: a comprehensive review. Clin Rev Allergy Immunol 2015; 49: 278\u201387","DOI":"10.1007\/s12016-014-8431-1"},{"key":"10.3238\/arztebl.2017.0354_ref9","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Brito-Zeron P, Solans R, et al.: Systemic involvement in primary Sj\u00f6gren\u2018s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology (Oxford) 2014; 53: 321\u201331","DOI":"10.1093\/rheumatology\/ket349"},{"key":"10.3238\/arztebl.2017.0354_ref10","doi-asserted-by":"crossref","unstructured":"Nishishinya MB, Pereda CA, Munoz-Fernandez S, et al.: Identification of lymphoma predictors in patients with primary Sj\u00f6gren\u2018s syndrome: a systematic literature review and meta-analysis. Rheumatol Int 2015; 35: 17\u201326","DOI":"10.1007\/s00296-014-3051-x"},{"key":"10.3238\/arztebl.2017.0354_ref11","doi-asserted-by":"crossref","unstructured":"Theander E, Vasaitis L, Baecklund E, et al.: Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren\u2018s syndrome. Ann Rheum Dis 2011; 70: 1363\u20138","DOI":"10.1136\/ard.2010.144782"},{"key":"10.3238\/arztebl.2017.0354_ref12","doi-asserted-by":"crossref","unstructured":"Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S: Pulmonary manifestations of Sj\u00f6gren\u2018s syndrome. Eur Respir Rev 2016; 25: 110\u201323","DOI":"10.1183\/16000617.0011-2016"},{"key":"10.3238\/arztebl.2017.0354_ref13","doi-asserted-by":"crossref","unstructured":"Evans R, Zdebik A, Ciurtin C, Walsh SB: Renal involvement in primary Sj\u00f6gren\u2018s syndrome. Rheumatology (Oxford) 2015; 549: 1541\u20138","DOI":"10.1093\/rheumatology\/kev223"},{"key":"10.3238\/arztebl.2017.0354_ref14","doi-asserted-by":"crossref","unstructured":"Pavlakis PP, Alexopoulos H, Kosmidis ML, et al.: Peripheral neuropathies in Sj\u00f6gren\u2018s syndrome: a critical update on clinical features and pathogenetic mechanisms. J Autoimmun 2012; 39: 27\u201333","DOI":"10.1016\/j.jaut.2012.01.003"},{"key":"10.3238\/arztebl.2017.0354_ref15","doi-asserted-by":"crossref","unstructured":"Harms L, Hiepe F: Neurological manifestations in connective tissue disease. Z Rheumatol 2012; 71: 564\u201371","DOI":"10.1007\/s00393-012-0958-z"},{"key":"10.3238\/arztebl.2017.0354_ref16","doi-asserted-by":"crossref","unstructured":"Westhoff G, D\u00f6rner T, Zink A: Fatigue and depression predict physician visits and work disability in women with primary Sjogren\u2018s syndrome: results from a cohort study. Rheumatology (Oxford) 2012; 51: 262\u20139","DOI":"10.1093\/rheumatology\/ker208"},{"key":"10.3238\/arztebl.2017.0354_ref17","doi-asserted-by":"crossref","unstructured":"Brito-Zeron P, Izmirly PM, Ramos-Casals M, Buyon JP, Khamashta MA: The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11: 301\u201312","DOI":"10.1038\/nrrheum.2015.29"},{"key":"10.3238\/arztebl.2017.0354_ref18","doi-asserted-by":"crossref","unstructured":"Singh AG, Singh S, Matteson EL: Rate, risk factors and causes of mortality in patients with Sj\u00f6gren\u2018s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2016; 55: 450\u201360.","DOI":"10.1093\/rheumatology\/kev354"},{"key":"10.3238\/arztebl.2017.0354_ref19","doi-asserted-by":"crossref","unstructured":"Moutsopoulos HM: Sj\u00f6gren\u2018s Syndrome: autoimmune epithelitis. Clinical Immunology and Immunopathology 1994; 72: 162\u20135","DOI":"10.1006\/clin.1994.1123"},{"key":"10.3238\/arztebl.2017.0354_ref20","doi-asserted-by":"crossref","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al.: 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2018s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017; 69: 35\u201345","DOI":"10.1002\/art.39859"},{"key":"10.3238\/arztebl.2017.0354_ref21","doi-asserted-by":"crossref","unstructured":"Cornec D, Devauchelle-Pensec V, Saraux A, Jousse-Joulin S: Clinical usefulness of salivary gland ultrasonography in Sj\u00f6gren\u2018s syndrome: where are we now? Rev Med Interne 2016; 37: 186\u201394","DOI":"10.1016\/j.revmed.2015.10.341"},{"key":"10.3238\/arztebl.2017.0354_ref22","doi-asserted-by":"crossref","unstructured":"Nardi N, Brito-Zeron P, Ramos-Casals M, et al.: Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sj\u00f6gren\u2018s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006; 25:\u00a0341\u20136","DOI":"10.1007\/s10067-005-0059-3"},{"key":"10.3238\/arztebl.2017.0354_ref23","doi-asserted-by":"crossref","unstructured":"Pisetsky DS: Antinuclear antibodies in healthy people: the tip of autoimmunity\u2018s iceberg? Arthritis Res Ther 2011; 13: 109","DOI":"10.1186\/ar3282"},{"key":"10.3238\/arztebl.2017.0354_ref24","doi-asserted-by":"crossref","unstructured":"Patel R, Shahane A: The epidemiology of Sj\u00f6gren\u2018s syndrome. Clin Epidemiol 2014; 6: 247\u201355","DOI":"10.2147\/CLEP.S47399"},{"key":"10.3238\/arztebl.2017.0354_ref25","doi-asserted-by":"crossref","unstructured":"Theander E, Jonsson R, Sjostrom B, Brokstad K, Olsson P, Henriksson G: Prediction of Sj\u00f6gren\u2018s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheumatol 2015; 67: 2427\u201336","DOI":"10.1002\/art.39214"},{"key":"10.3238\/arztebl.2017.0354_ref26","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Seror R, Miceli-Richard C, et al.: Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren\u2018s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013; 8: e59868","DOI":"10.1371\/journal.pone.0059868"},{"key":"10.3238\/arztebl.2017.0354_ref27","doi-asserted-by":"crossref","unstructured":"Rose T, Szelinski F, Lisney A, et al.: SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren\u2018s syndrome. RMD Open 2016; 2: e000292","DOI":"10.1136\/rmdopen-2016-000292"},{"key":"10.3238\/arztebl.2017.0354_ref28","doi-asserted-by":"crossref","unstructured":"Daniels TE, Cox D, Shiboski CH, et al.: Associations between salivary gland histopathologic diagnoses and phenotypic features of Sj\u00f6gren\u2018s syndrome among 1,726 registry participants. Arthritis Rheum 2011; 63: 2021\u201330","DOI":"10.1002\/art.30381"},{"key":"10.3238\/arztebl.2017.0354_ref29","doi-asserted-by":"crossref","unstructured":"Seror R, Bowman SJ, Brito-Zeron P, et al.: EULAR Sj\u00f6gren\u2018s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015; 1: e000022","DOI":"10.1136\/rmdopen-2014-000022"},{"key":"10.3238\/arztebl.2017.0354_ref30","doi-asserted-by":"crossref","unstructured":"Saraux A, Pers JO, Devauchelle-Pensec V: Treatment of primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 2016; 12: 456\u201371","DOI":"10.1038\/nrrheum.2016.100"},{"key":"10.3238\/arztebl.2017.0354_ref31","doi-asserted-by":"crossref","unstructured":"Leonardi A, Van Setten G, Amrane M, et al.: Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol 2016; 26: 287\u201396","DOI":"10.5301\/ejo.5000779"},{"key":"10.3238\/arztebl.2017.0354_ref32","doi-asserted-by":"crossref","unstructured":"Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS: Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000; 130: 25\u201332","DOI":"10.1016\/S0002-9394(00)00378-0"},{"key":"10.3238\/arztebl.2017.0354_ref33","doi-asserted-by":"crossref","unstructured":"Furness S, Worthington HV, Bryan G, Birchenough S, McMillan R: Interventions for the management of dry mouth: topical therapies. Cochrane Database Syst Rev 2011; (12): CD008934","DOI":"10.1002\/14651858.CD008934.pub2"},{"key":"10.3238\/arztebl.2017.0354_ref34","doi-asserted-by":"crossref","unstructured":"Furness S, Bryan G, McMillan R, Worthington HV: Interventions for the management of dry mouth: non-pharmacological interventions. Cochrane Database Syst Rev 2013; (8): CD009603","DOI":"10.1002\/14651858.CD009603.pub2"},{"key":"10.3238\/arztebl.2017.0354_ref35","doi-asserted-by":"crossref","unstructured":"Albrecht K, Callhoff J, Westhoff G, Dietrich T, Dorner T, Zink A: The prevalence of dental implants and related factors in patients with Sjogren syndrome: results from a cohort study. J Rheumatol 2016; 43: 1380\u20135","DOI":"10.3899\/jrheum.151167"},{"key":"10.3238\/arztebl.2017.0354_ref36","doi-asserted-by":"crossref","unstructured":"Carsons SE, Vivino FB, Parke A, et al.: Treatment guidelines for rheumatologic manifestations of Sjogren\u2018s: use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res (Hoboken) 2016.","DOI":"10.1002\/acr.22968"},{"key":"10.3238\/arztebl.2017.0354_ref37","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Ravaud P, Puechal X, et al.: Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 2014; 312: 249\u201358","DOI":"10.1001\/jama.2014.7682"},{"key":"10.3238\/arztebl.2017.0354_ref38","doi-asserted-by":"crossref","unstructured":"Dass S, Bowman SJ, Vital EM, et al.: Reduction of fatigue in Sj\u00f6gren\u2019s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis 2008; 67: 1541\u20134","DOI":"10.1136\/ard.2007.083865"},{"key":"10.3238\/arztebl.2017.0354_ref39","unstructured":"Bowman S, Everett C, Bombardieri M, et al.: Preliminary results of a double-blind randomised trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome. Arthritis Rheumatol 2015; 67: 3955\u20137."},{"key":"10.3238\/arztebl.2017.0354_ref40","doi-asserted-by":"crossref","unstructured":"Izmirly PM, Kim MY, Llanos C, et al.: Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 6910: 1827\u201330","DOI":"10.1136\/ard.2009.119263"},{"key":"10.3238\/arztebl.2017.0354_ref41","doi-asserted-by":"crossref","unstructured":"Segal BM, Pogatchnik B, Holker E, et al.: Primary Sjogren\u2019s syndrome: cognitive symptoms, mood, and cognitive performance. Acta Neurol Scand 2012; 125: 272\u20138","DOI":"10.1111\/j.1600-0404.2011.01530.x"},{"key":"10.3238\/arztebl.2017.0354_ref42","doi-asserted-by":"crossref","unstructured":"Cruz-Tapias P, Rojas-Villarraga A, Maier-Moore S, Anaya JM: HLA and Sj\u00f6gren\u2018s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev 2012; 11: 281\u20137","DOI":"10.1016\/j.autrev.2011.10.002"},{"key":"10.3238\/arztebl.2017.0354_ref43","doi-asserted-by":"crossref","unstructured":"Reksten TR, Lessard CJ, Sivils KL: Genetics in Sj\u00f6gren syndrome. Rheum Dis Clin North Am 2016; 42: 435\u201347","DOI":"10.1016\/j.rdc.2016.03.003"},{"key":"10.3238\/arztebl.2017.0354_ref44","doi-asserted-by":"crossref","unstructured":"Hall JC, Baer AN, Shah AA, et al.: Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol 2015; 67: 2437\u201346","DOI":"10.1002\/art.39204"},{"key":"10.3238\/arztebl.2017.0354_ref45","doi-asserted-by":"crossref","unstructured":"Mavragani CP, Crow MK: Activation of the type I interferon pathway in primary Sj\u00f6gren\u2018s syndrome. J Autoimmun 2010; 35: 225\u201331","DOI":"10.1016\/j.jaut.2010.06.012"},{"key":"10.3238\/arztebl.2017.0354_ref46","doi-asserted-by":"crossref","unstructured":"Hansen A, D\u00f6rner T: Sj\u00f6gren syndrom. Internist (Berl) 2010; 51: 1267\u201379","DOI":"10.1007\/s00108-010-2720-4"},{"key":"10.3238\/arztebl.2017.0354_ref47","doi-asserted-by":"crossref","unstructured":"Seror R, Theander E, Brun JG, et al.: Validation of EULAR primary Sj\u00f6gren\u2018s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015; 74: 859\u201366","DOI":"10.1136\/annrheumdis-2013-204615"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T10:24:33Z","timestamp":1638872673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2017.0354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":47,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2017.0354","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]}}}